Key Details
Price
$1.72Annual ROE
-24.66%Beta
0.67Events Calendar
Next earnings date:
Mar 28, 2025Recent quarterly earnings:
Jul 25, 2024Recent annual earnings:
Mar 29, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Dublin, Jan. 29, 2025 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight & Market Opportunity Outlook 2028" report has been added to ResearchAndMarkets.com's offering.
SAN DIEGO and SUZHOU, China, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced it will share updated clinical data from ADG126 in microsatellite stable colorectal cancer (MSS CRC) at the ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA on Saturday, January 25, 2025.
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Here is how Adagene Inc. Sponsored ADR (ADAG) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year.
Here is how Adagene Inc. Sponsored ADR (ADAG) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
SAN DIEGO and SUZHOU, China, July 12, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a poster presentation at the upcoming ESMO Congress, taking place in Barcelona, Spain, 13-17 September 2024.
SAN DIEGO and SUZHOU, China, May 22, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its participation in multiple investor conferences in June 2024.
- Interim results in MSS CRC suggest that SAFEbody precision masking technology enables a new standard for anti-CTLA-4 therapy at higher, more frequent and repeat doses by overcoming longtime safety-limited efficacy challenges with this proven immunotherapy target -
Here is how Adagene Inc. Sponsored ADR (ADAG) and AN2 Therapeutics, Inc. (ANTX) have performed compared to their sector so far this year.
Here is how Adagene Inc. Sponsored ADR (ADAG) and Alcon (ALC) have performed compared to their sector so far this year.
FAQ
- What is the ticker symbol for Adagene?
- Does Adagene pay dividends?
- What sector is Adagene in?
- What industry is Adagene in?
- What country is Adagene based in?
- When did Adagene go public?
- Is Adagene in the S&P 500?
- Is Adagene in the NASDAQ 100?
- Is Adagene in the Dow Jones?
- When was Adagene's last earnings report?
- When does Adagene report earnings?
- Should I buy Adagene stock now?